|
|
|
Insider
Information: |
Woiwode Thomas |
Relationship: |
Director, 10% Owner |
City: |
Menlo Park |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
4,055,448 |
|
Indirect Shares
|
9,833,794 |
|
|
Direct
Value |
$4,729,041 |
|
|
Indirect Value
|
$48,638,558 |
|
|
Total
Shares |
13,889,242 |
|
|
Total
Value |
$53,367,599 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
Percentage
Gain/Loss : |
-14.8%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Adverum Biotechnologies, Inc |
ADVM |
Director |
2020-12-14 |
18,822 |
2016-05-11 |
0 |
Premium* |
|
Crispr Therapeutics Ag |
CRSP |
Director |
2018-05-15 |
5,629 |
2018-05-15 |
640,014 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Director |
2021-08-25 |
128 |
2021-08-25 |
3,102,929 |
Premium* |
|
Passage Bio, Inc. |
PASG |
Director, 10% Owner |
2020-03-03 |
4,026,417 |
2020-03-03 |
933,352 |
Premium* |
|
Aligos Therapeutics, Inc. |
ALGS |
Director |
2021-06-11 |
4,452 |
2021-06-11 |
862,444 |
Premium* |
|
Tempest Therapeutics, Inc |
TPST |
Director, 10% Owner |
2021-06-25 |
0 |
2022-04-29 |
4,295,055 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TPST |
Tempest Therapeutics, Inc |
|
|
2021-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,176,411 |
7,377 |
0 |
- |
|
TPST |
Tempest Therapeutics, Inc |
Director |
|
2022-04-29 |
4 |
B |
$2.36 |
$5,000,000 |
I/I |
2,118,644 |
2,118,644 |
2.25 |
- |
|
PASG |
Passage Bio, Inc. |
Director |
|
2020-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
708,352 |
708,352 |
0 |
- |
|
PASG |
Passage Bio, Inc. |
Director |
|
2020-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,026,417 |
4,026,417 |
0 |
- |
|
PASG |
Passage Bio, Inc. |
Director |
|
2020-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
4,734,769 |
708,352 |
0 |
- |
|
PASG |
Passage Bio, Inc. |
Director |
|
2020-03-03 |
4 |
B |
$18.00 |
$4,050,000 |
I/I |
225,000 |
933,352 |
2.25 |
% |
|
GRTS |
Gritstone Oncology, Inc. |
Director |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,102,929 |
3,102,929 |
0 |
- |
|
GRTS |
Gritstone Oncology, Inc. |
Director |
|
2021-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
128 |
128 |
0 |
- |
|
GRTS |
Gritstone Oncology, Inc. |
Director |
|
2021-08-25 |
4 |
AS |
$0.00 |
$0 |
I/I |
(458,024) |
0 |
0 |
% |
|
GRTS |
Gritstone Oncology, Inc. |
Director |
|
2021-08-25 |
4 |
A |
$0.00 |
$0 |
I/I |
13,280 |
6,612 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
239,648 |
|
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2016-10-18 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
923,662 |
|
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
342,007 |
|
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2016-10-24 |
4 |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
2.1 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-09-05 |
4 |
A |
$0.00 |
$0 |
D/D |
9,918 |
9,918 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-09-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,614,157) |
0 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-09-05 |
4 |
A |
$0.00 |
$0 |
I/I |
311,052 |
1,240 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-11-24 |
4 |
AS |
$20.21 |
$34,358 |
D/D |
(1,700) |
8,218 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-11-27 |
4 |
AS |
$20.24 |
$4,048 |
D/D |
(200) |
8,018 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-12-22 |
4 |
AS |
$20.29 |
$62,070 |
D/D |
(3,059) |
4,959 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,323 |
7,282 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-04-20 |
4 |
AS |
$0.00 |
$0 |
I/I |
(592,918) |
0 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-04-20 |
4 |
A |
$0.00 |
$0 |
I/I |
92,918 |
92,918 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-04-23 |
4 |
AS |
$50.66 |
$5,168,901 |
I/I |
(101,994) |
117,173 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|